Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2129 Phase 1 SAD and Food Effect Study
NCT06619392Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-2129 in pain (5 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Incidence and severity of adverse events. Started Oct 2024; status: completed.
02
Drugs
HRS-2129
03
Conditions
pain
Beyond the preview
Go deeper on NCT06619392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619392.